Clinical Usefulness of a Cell-based Assay for Detecting Myelin Oligodendrocyte Glycoprotein Antibodies in Central Nervous System Inflammatory Disorders
- Authors
- Seok, Jin Myoung; Waters, Patrick; Jeon, Mi Young; Lee, Hye Lim; Baek, Seol-Hee; Park, Jin-Sung; Kang, Sa-Yoon; Kwon, Ohyun; Oh, Jeeyoung; Kim, Byung-Jo; Park, Kyung-Ah; Oh, Sei Yeul; Kim, Byoung Joon; Min, Ju-Hong
- Issue Date
- Jan-2024
- Publisher
- 대한진단검사의학회
- Keywords
- Autoantibody; Central nervous system disease; Immunoassay; Myelin oligo-dendrocyte glycoprotein
- Citation
- Annals of Laboratory Medicine, v.44, no.1, pp.56 - 63
- Indexed
- SCIE
SCOPUS
KCI
OTHER
- Journal Title
- Annals of Laboratory Medicine
- Volume
- 44
- Number
- 1
- Start Page
- 56
- End Page
- 63
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2021.sw.kumedicine/64249
- DOI
- 10.3343/alm.2024.44.1.56
- ISSN
- 2234-3806
- Abstract
- Background: The clinical implications of myelin oligodendrocyte glycoprotein autoantibodies (MOG-Abs) are increasing. Establishing MOG-Ab assays is essential for effectively treating patients with MOG-Abs. We established an in-house cell-based assay (CBA) to detect MOG-Abs to identify correlations with patients' clinical characteristics. Methods: We established the CBA using HEK 293 cells transiently overexpressing fulllength human MOG, tested it against 166 samples from a multicenter registry of central nervous system (CNS) inflammatory disorders, and compared the results with those of the Oxford MOG-Ab-based CBA and a commercial MOG-Ab CBA kit. We recruited additional patients with MOG-Abs and compared the clinical characteristics of MOG-Ab-associated disease (MOGAD) with those of neuromyelitis optica spectrum disorder (NMOSD). Results: Of 166 samples tested, 10 tested positive for MOG-Abs, with optic neuritis (ON) being the most common manifestation (4/15, 26.7%). The in-house and Oxford MOG-Ab CBAs agreed for 164/166 (98.8%) samples (kappa= 0.883, P < 0.001); two patients (2/166, 1.2%) were only positive in our in-house CBA, and the CBA scores of the two laboratories correlated well (r=0.663, P < 0.001). The commercial MOG-Ab CBA kit showed one false negative and three false-positive results. The clinical presentation at disease onset differed between MOGAD and NMOSD; ON was the most frequent manifestation in MOGAD, and transverse myelitis was most frequent in NMOSD. Conclusions: The in-house CBA for MOG-Abs demonstrated reliable results and can potentially be used to evaluate CNS inflammatory disorders. A comprehensive, long-term study with a large patient population would clarify the clinical significance of MOG-Abs.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 2. Clinical Science > Department of Neurology > 1. Journal Articles

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.